Detection of Multidrug Resistance Activity Using Flow Cytometry as a Diagnostic Tool

Fri14  Oct04:15pm(30 mins)
 Gergely Toldi


Multidrug resistance (MDR) protein activity is an
independent prognostic marker in certain haematological malignancies. Immune
activation is also linked to the expression of MDR proteins in autoimmune
disorders. High activity of these transporters in target cells is the most
common mechanism of resistance to chemotherapeutic and immunosuppressive
agents. The SOLVO MDQ Kitâ„¢ enables a more accurate prediction of drug
resistance than other methods such as quantifying the expression of the
transporters at mRNA or protein level. Determination of transporter activities
allows risk stratification of patients by predicting resistance to certain
cytotoxic agents in hematology. In resistant cases the chances for better
patient outcomes are higher by alternative treatment choices, and the costs of
ineffective treatment can be saved. Furthermore, MDR protein function may
predict patient response to traditional DMARD, as well as biological treatment
in rheumatology, quantifying the actual disease activity of RA patients. Our
recent results suggest that low BCRP/ABCG2 and MRP1/ABCC1 protein activities on
CD3 cells of RA patients whose symptoms do not improve on classical DMARD
treatment reflect the need to start biological therapy. Further decrease of CD3
BCRP/ABCG2 and increase in CD3 MRP1/ABCC1 activities upon follow-up may
indicate a good therapeutic response to biological therapy.

Hosted By


The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2022